Novartis: trial shows durable responses with Kymriah

(CercleFinance.com) - A pivotal clinical trial that lasted over one year showed strong efficacy with durable responses with Kymriah when administered to adult patients with relapsed or refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma, Novartis said on Monday.


The overall response rate was 52% among 93 patients, with a complete response achieved in 40% of patients while 12% achieved a partial response, the Swiss drugmaker said.

In the study, patients had a 65% chance of being relapse-free one year after onset of response, the company said.

Approved by the US Food and Drug Administration (FDA) in May 2018, Kymriah may cause severe or life-threatening side effects, such as breathing difficulties, fever, severe nausea, vomiting and diarrhea.

Copyright (c) 2018 CercleFinance.com. All rights reserved.